Abstract
Compared with warfarin, the new target-specific oral anticoagulant agents may have advantages, such as shorter hospital length of stay, in patients with nonvalvular atrial fibrillation (NVAF). The objective of the present study was to assess, among patients with NVAF, the effects of rivaroxaban versus warfarin on the number of hospitalization days and other health care resource utilization in a cohort of rivaroxaban users and matched warfarin users. Data from health care claims dated from May 2011 to December 2012 from the Humana database were analyzed. Adult patients newly initiated on treatment with rivaroxaban or warfarin, with ≥2 diagnoses of AF (ICD-9-CM code 427.31), and without valvular AF were identified. Based on propensity score methods, warfarin recipients were matched 1:1 to rivaroxaban recipients. The end of the observation period was defined as the end of data availability, the end of insurance coverage, death, the date of a switch to another anticoagulant agent, or day 14 of treatment nonpersistence. The total number of hospitalization days and other health care resource utilization parameters (numbers of hospitalizations, emergency department [ED] visits, and outpatient visits) were evaluated using the method by...Continue Reading
References
Apr 12, 2001·Journal of Clinical Epidemiology·S T NormandB J McNeil
Jul 30, 2003·Circulation·Wendy A WattigneyJanet B Croft
Nov 19, 2009·Journal of Thrombosis and Thrombolysis·Scott Kaatz
Jan 1, 2010·The New England Journal of Medicine·Donald Stuart Houston, Ryan Zarychanski
May 5, 2011·Circulation. Cardiovascular Quality and Outcomes·Michael H KimKathy L Schulman
Aug 30, 2011·The New England Journal of Medicine·Christopher B GrangerUNKNOWN ARISTOTLE Committees and Investigators
Dec 15, 2012·Circulation·Alan S GoUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Jan 4, 2013·Circulation·Alan S GoUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Jan 10, 2013·Journal of Postgraduate Medicine·S Aditya
Jun 14, 2013·Current Atherosclerosis Reports·Graeme J Hankey, John W Eikelboom
Nov 22, 2013·Current Medical Research and Opinion·François LalibertéPatrick Lefebvre
Citations
Jan 29, 2016·Expert Review of Pharmacoeconomics & Outcomes Research·Nicola Lucio Liberato, Monia Marchetti
Apr 22, 2015·Advances in Therapy·François LalibertéPatrick Lefebvre
Mar 31, 2016·Journal of Medical Economics·Lin XieJeffrey Trocio
Feb 20, 2018·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Lara M GroetzingerBelinda N Rivera-Lebron
Jan 13, 2018·Clinical Pharmacology and Therapeutics·Jonathan C Hsu, James V Freeman
Jan 8, 2019·Journal of Medical Economics·Lisa Aniek de JongMaarten J Postma
Nov 22, 2018·American Journal of Therapeutics·Wilbert S Aronow, Tatyana A Shamliyan
Sep 1, 2019·BMJ Open·Ruijin QiuHongcai Shang
Nov 17, 2015·Current Opinion in Cardiology·Christopher J Boos, Louise Brown
Apr 23, 2020·Journal of Population Therapeutics and Clinical Pharmacology Journal De La Thérapeutique Des Populations Et De La Pharamcologie Clinique·Anne HolbrookEleanor Pullenyegum
Aug 7, 2017·SAGE Open Medicine·Catherine A SaintErin K Hennessey
Apr 30, 2021·Journal of Medical Economics·Jeffrey S BergerVeronica Ashton
Aug 12, 2021·Journal of Comparative Effectiveness Research·François LalibertéJeffrey S Berger
Aug 28, 2021·Journal of Clinical Medicine·Ancuța Elena VîjanGheorghe-Andrei Dan